Resources from the same session
1254MO - Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
Presenter: Antonio Passaro
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1255MO - A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Presenter: Yi-Long Wu
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1256MO - Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
Presenter: Benjamin Besse
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1257MO - ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
Presenter: María De Miguel
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1258MO - Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial
Presenter: Michel van den Heuvel
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1257MO and 1258MO
Presenter: Mariana Brandão
Session: Mini oral session: NSCLC metastatic
Resources:
Slides
Webcast
LBA56 - Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Presenter: Gregory Riely
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
LBA57 - Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
Presenter: Fabrice Barlesi
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
Presenter: David Planchard
Session: Mini oral session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA56, LBA57 and 1259MO
Presenter: Sai-Hong Ou
Session: Mini oral session: NSCLC metastatic
Resources:
Slides
Webcast